Country: Singapore
Language: English
Source: HSA (Health Sciences Authority)
MESTEROLONE
BAYER (SOUTH EAST ASIA) PTE LTD
G03BB01
25 mg
TABLET
ORAL
Prescription Only
Schering Do Brasil,Quimica e Farmaceutica Ltda.
1990-06-28
Provironum PI_SG_CCDS_26 June 2013 PROVIRONUM For oral androgen therapy in the male COMPOSITION 1 white tablet of Provironum contains 25 mg mesterolone. _ _ PHARMACODYNAMIC PROPERTIES Provironum balances a deficiency of androgen formation which begins to fall gradually with increasing age. Therefore, Provironum is suitable for the treatment of all conditions caused by deficient endogenous androgen formation. In the recommended therapeutic dosage, Provironum will not impair spermatogenesis. Provironum is especially well tolerated by the liver. PHARMACOKINETIC PROPERTIES Following oral ingestion mesterolone is rapidly and almost completely absorbed in a dose range of 25 - 100 mg. The intake of Provironum generates maximum serum drug levels of 3.1 ± 1.1 ng/ml after 1.6 ± 0.6 hours. Thereafter, drug levels in serum decrease with a terminal half-life of 12 - 13 hours. Mesterolone is bound to serum proteins by 98 %. Binding to albumin accounts for 40 % and binding to SHBG (sex hormone binding globulin) to 58 %. Mesterolone is rapidly inactivated by metabolism. The metabolic clearance rate from serum accounts for 4.4 ± 1.6 ml·min -1 ·kg -1 . There is no renal excretion of unchanged drug. The main metabolite has been identified as 1α-methyl-androsterone, which - in conjugated form - accounts for 55 - 70 % of renally excreted metabolites. The ratio of main metabolite glucuronide to sulphate was about 12:1. As a further metabolite 1α-methyl-5α-androst Read the complete document